Woodland Biosciences and CNBE – INRS extend oncology alliance to now include liver diseases

The partners extend their alliance to now include NASH / Fibrosis / Fatty Liver Disease or Steatosis and their sequelae HCC, or liver cancer to augment their oncology offerings.
By: Woodland Pharmaceuticals, CNBE-INRS
 
GRAFTON, Mass. - Aug. 24, 2015 - PRLog -- Grafton, MA, U.S.A. and Laval, Quebec August 13, 2015. – Earlier this year a strategic partnership agreement in preclinical oncology was signed by Woodland Biosciences and Centre national de biologie expérimentale (CNBE) of Institut national de recherche scientifique (INRS). This unique alliance provided integrated contractual services from target discovery through preclinical development in the oncology field. Now we announce an expansion of preclinical services to encompass a broad spectrum of liver disease states, starting with obesity, diabetes, fatty liver disease or steatosis and inflammatory diseases such as liver fibrosis.  All of these prequelae can lead to liver cancer, hepatocellular carcinoma or HCC and our models develop liver cancers if the disease is allowed to progress to its natural conclusion.

Liver diseases including fatty liver and diabetes are rapidly becoming one of the most pressing needs in the medical community as the population grows and ages. Our new spectrum of services comprises in vivo pharmacology studies of the progression of liver disease in mouse models. In addition to standard efficacy studies, the alliance allows us to provide the following expanded and integrated menu of services making the sponsor’s experiment a more complete study that can be customized to customer needs: screening toxicology (biodistribution, maximum tolerated dose, dose-range finding, immunotoxicology,), pharmacokinetic, pharmacodynamic and biomarker identification in healthy and diseased animals.

Further, in partnership with CNBE, Woodland and its academic partner are expanding model research and development to include a rat model of Type 2 diabetes and NASH / fibrosis to complement the current model in male C57BL6 mice.  Until now model offerings from CROs around the globe offered only male mouse model of fibrosis, however exciting new data from Woodland research shows for the first time liver fibrosis in female mice.  This work is offered as a developmental model for interested parties from our new research facilities in Laval, Canada or in our Massachusetts laboratories.

“This exciting new field of experimental model research opens new doors into the burgeoning field of liver diseases including fibrosis, cirrhosis and liver cancer as well as the complications of obesity and diabetes such as fatty liver disease,” explains Dr. Michael R. Briggs, President of Woodland Biosciences.

“Thanks to this agreement, the clients will be able to use the expertise of each organisation to strengthen their drug development pipeline. They will have also the possibility to expand their development in using the state-of-art animal facility of the CNBE having the expertise and capability to house rodents, rabbits, dogs, ferrets, farm animals (swine, sheep, goats and fowls) and non-human primates,” adds Dr. Mario C. Filion, Director of CNBE-INRS.  We welcome inquiries into model expansion and/or development in these species as well.

About Woodland Biosciences

Woodland BioSciences is a preclinical contract research organization (CRO) providing innovative and customized solutions and consultation to the biotechnology community. The mission of Woodland is to enhance drug development for the most severe cancers, inflammation and other major diseases.
Woodland also enters shared-risk ventures through our bioincubator to help advance early molecules to value creation milestones.

About CNBE INRS

CNBE, located on the INRS campus in Laval, offers high standard preclinical research services to the scientific community and the biotechnology and pharmaceutical industries. Certified by the Canadian Council on Animal Care in Science (CCAC) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International), it provides housing for laboratory animals at various levels of biological confinement as well as an array of services required by R&D projects.

Source:

Michael R. Briggs          Mario C. Filion

President          Director

Woodland Bioscience          CNBE INRS

Worcester, MA, USA          Laval, Québec, Canada

mbriggs@woodlandpharma.com          Mario.Filion@iaf.inrs.ca (https://email10.secureserver.net/search.php)

www.woodlandbiosciences.com          www.cnbe.inrs.ca

Contact
Michael Briggs (Woodland), Mario Filion (CNBE)
mbriggs@woodlandpharma.com
End
Source:Woodland Pharmaceuticals, CNBE-INRS
Email:***@woodlandpharma.com Email Verified
Tags:NASH / FLD, Fatty Liver Disease Model, Liver Fibrosis
Industry:Biotech
Location:Grafton - Massachusetts - United States
Subject:Services
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Woodland Pharmaceuticals PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share